Clinical trials: copd or chronic obstructive
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease.
- Trial name
- NCT01680991
- Testing
- Obinutuzumab
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD
At Home Spirometry and Video Module Education for COPD Patients
The central hypothesis is that patients hospitalized for COPD who subsequently complete the at-home BREATHES Program with V-TTG skill training and SpiroPD adherence support will retain increased medication knowledge, skill…
- Trial name
- BREATHES (NCT03834350)
- Testing
- BREATHES Program, BREATHES SpiroPD or Propeller Health
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of Chicago
Chronic Obstructive Pulmonary Disease, Heart Failure
PATient Navigator to rEduce Readmissions
Staying out of the hospital is valued by patients and their caregivers. Their interests converge with those of hospitals now that high 30-day readmission rates for some conditions place hospitals at risk for financial penalties…
- Conditions
- Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction
- Trial name
- PArTNER (NCT02114515)
- Testing
- Hospital usual care, Navigator intervention, Peer-led telephone support line
- Where
- United States
- Volunteers
- 1,029 people
- Sponsor
- University of Illinois Chicago
Chronic Obstructive Pulmonary Disease
Vagus Nerve Stimulation for Management of Bronchoconstriction in Patients Hospitalized With COPD Exacerbations
This study will look at the safety, improving symptoms and decreasing the length of stay of patients admitted to the hospital with COPD.
- Trial name
- NCT01612793
- Testing
- AlphaCore Device
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- ElectroCore INC
COPD Asthma
Pulmonary Specialist-Health Coach Consult Model Study
The Pulmonary Specialist-Health Coach Consultation (PuSHCon) study examines the implementation of health coach-assisted consultations to improve access to specialist care and implementation of specialist recommendations for…
- Trial name
- PuSHCon (NCT03695276)
- Testing
- PushCon Model, Usual care
- Where
- 11 sites in United States
- Volunteers
- 328 people
- Sponsor
- University of California, San Francisco
Pulmonary Disease, Chronic Obstructive
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a…
- Trial name
- NCT03170232
- Testing
- Danirixin 35 mg tablets, Metered dose inhaler (MDI) sensor device, Rescue medication
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered…
- Trial name
- NCT00400153
- Testing
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg)
- Where
- 180 sites in United States, Argentina and 11 more
- Volunteers
- 1,480 people
- Sponsor
- Boehringer Ingelheim
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans
Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS).
- Conditions
- Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
- Trial name
- NCT01650545
- Testing
- Liposomal aerosol cyclosporine, standard immune suppression, oral
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Asthma
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
The study is to evaluate the chronic-dose efficacy and the safety of Albuterol MDPI compared to placebo in pediatric participants with asthma.
- Trial name
- NCT02126839
- Testing
- Albuterol MDPI, ProAir HFA inhaler
- Where
- 52 sites in United States, Thailand
- Volunteers
- 186 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Low Back Pain, Neuropathic Pain
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
The main objective of the study is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a combination of tapentadol PR (300 mg per day) and…
- Trial name
- NCT01352741
- Testing
- Tapentadol Prolonged Release, Tapentadol Prolonged Release with Pregabalin, Tapentadol Prolonged Release open label maintenance
- Where
- 59 sites in Austria, Belgium and 5 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen…
- Trial name
- NCT00403845
- Testing
- Indacaterol 150 μg, Indacaterol 300 μg
- Where
- 8 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Preference Tiotropium Respimat Study in COPD
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD.
- Trial name
- NCT01810692
- Testing
- Group1:Spiriva® Respimat®, Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
- Where
- 15 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
COPD Patients and Patients Recovering From COVID19
Increasing Physical Activity in COPD Through Rhythmically Enhanced Music
The VA cares for nearly one million Veterans with COPD at a cost of more than $5.5 billion annually. COPD profoundly impairs quality of life as it limits ability to work, to maintain physical exertion and to engage in social…
- Trial name
- NCT03655028
- Testing
- rhythmically auditory stimulation enhanced music, control
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Pulmonary Embolism, Chronic Obstructive Pulmonary Disease
Pulmonary Embolism as a Cause of COPD Exacerbations
The primary objective is to demonstrate the clinical benefits of an active strategy for the diagnosis and treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who require hospital admission.
- Trial name
- SLICE (NCT02238639)
- Testing
- Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).
- Where
- 19 sites in Spain
- Volunteers
- 746 people
- Sponsor
- Ministry of Health, Spain
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Spinal Cord Injury, Sleep Apnea, Obstructive
Sleep-Disordered Breathing in Chronic SCI
The purpose of this study is to examine impact of Sleep Disordered Breathing (SDB) treatment in persons with chronic Spinal Cord Injury (SCI).
- Trial name
- NCT02176928
- Testing
- AutoPAP
- Where
- 4 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Miami
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder and GW642444 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316900
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444
- Where
- 97 sites in United States, France and 8 more
- Volunteers
- 846 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.